<?xml version='1.0' encoding='utf-8'?>
<document id="20032533"><sentence text="Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries."><entity charOffset="49-59" id="DDI-PubMed.20032533.s1.e0" text="rifampicin" /></sentence><sentence text="Coadministration of antitubercular and antiretroviral therapy is common in high-burden countries where tuberculosis is the commonest opportunistic infection" /><sentence text=" Concomitant use of rifampicin and many antiretroviral drugs is complicated by drug-drug interactions caused by the potent induction by rifampicin of genes involved in drug metabolism and transport, which could result in subtherapeutic antiretroviral drug concentrations"><entity charOffset="20-30" id="DDI-PubMed.20032533.s3.e0" text="rifampicin" /><entity charOffset="136-146" id="DDI-PubMed.20032533.s3.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.20032533.s3.e0" e2="DDI-PubMed.20032533.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20032533.s3.e0" e2="DDI-PubMed.20032533.s3.e1" /></sentence><sentence text=" This review focuses on drug-drug interactions involving antiretrovirals used in resource-limited settings: the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz or nevirapine, and ritonavir-boosted protease inhibitors"><entity charOffset="169-178" id="DDI-PubMed.20032533.s4.e0" text="efavirenz" /><entity charOffset="182-192" id="DDI-PubMed.20032533.s4.e1" text="nevirapine" /><entity charOffset="198-207" id="DDI-PubMed.20032533.s4.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.20032533.s4.e0" e2="DDI-PubMed.20032533.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20032533.s4.e0" e2="DDI-PubMed.20032533.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s4.e0" e2="DDI-PubMed.20032533.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20032533.s4.e1" e2="DDI-PubMed.20032533.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s4.e1" e2="DDI-PubMed.20032533.s4.e2" /></sentence><sentence text=" The reduction of nevirapine concentrations with concomitant rifampicin is greater than with efavirenz, particularly during the lead-in dose period when subtherapeutic concentrations occur in the majority of patients"><entity charOffset="18-28" id="DDI-PubMed.20032533.s5.e0" text="nevirapine" /><entity charOffset="61-71" id="DDI-PubMed.20032533.s5.e1" text="rifampicin" /><entity charOffset="93-102" id="DDI-PubMed.20032533.s5.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.20032533.s5.e0" e2="DDI-PubMed.20032533.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20032533.s5.e0" e2="DDI-PubMed.20032533.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s5.e0" e2="DDI-PubMed.20032533.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20032533.s5.e1" e2="DDI-PubMed.20032533.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s5.e1" e2="DDI-PubMed.20032533.s5.e2" /></sentence><sentence text=" There is reassuring data on the effectiveness of standard doses of efavirenz with concomitant rifampicin, but the largest cohort study found a higher risk of virological failure with nevirapine"><entity charOffset="68-77" id="DDI-PubMed.20032533.s6.e0" text="efavirenz" /><entity charOffset="95-105" id="DDI-PubMed.20032533.s6.e1" text="rifampicin" /><entity charOffset="184-194" id="DDI-PubMed.20032533.s6.e2" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.20032533.s6.e0" e2="DDI-PubMed.20032533.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20032533.s6.e0" e2="DDI-PubMed.20032533.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s6.e0" e2="DDI-PubMed.20032533.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20032533.s6.e1" e2="DDI-PubMed.20032533.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s6.e1" e2="DDI-PubMed.20032533.s6.e2" /></sentence><sentence text=" The drug-drug interaction between rifampicin and ritonavir-boosted protease inhibitors is more marked than with the NNRTIs, and therapeutic concentrations have only been achieved with adjusted doses of lopinavir/ritonavir or with saquinavir/ritonavir (400/400 mg every 12 h)"><entity charOffset="35-45" id="DDI-PubMed.20032533.s7.e0" text="rifampicin" /><entity charOffset="50-59" id="DDI-PubMed.20032533.s7.e1" text="ritonavir" /><entity charOffset="203-212" id="DDI-PubMed.20032533.s7.e2" text="lopinavir" /><entity charOffset="213-222" id="DDI-PubMed.20032533.s7.e3" text="ritonavir" /><entity charOffset="231-241" id="DDI-PubMed.20032533.s7.e4" text="saquinavir" /><entity charOffset="242-251" id="DDI-PubMed.20032533.s7.e5" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e0" e2="DDI-PubMed.20032533.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e0" e2="DDI-PubMed.20032533.s7.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e0" e2="DDI-PubMed.20032533.s7.e2" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e0" e2="DDI-PubMed.20032533.s7.e3" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e0" e2="DDI-PubMed.20032533.s7.e4" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e0" e2="DDI-PubMed.20032533.s7.e5" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e1" e2="DDI-PubMed.20032533.s7.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e1" e2="DDI-PubMed.20032533.s7.e2" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e1" e2="DDI-PubMed.20032533.s7.e3" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e1" e2="DDI-PubMed.20032533.s7.e4" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e1" e2="DDI-PubMed.20032533.s7.e5" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e2" e2="DDI-PubMed.20032533.s7.e2" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e2" e2="DDI-PubMed.20032533.s7.e3" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e2" e2="DDI-PubMed.20032533.s7.e4" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e2" e2="DDI-PubMed.20032533.s7.e5" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e3" e2="DDI-PubMed.20032533.s7.e3" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e3" e2="DDI-PubMed.20032533.s7.e4" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e3" e2="DDI-PubMed.20032533.s7.e5" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e4" e2="DDI-PubMed.20032533.s7.e4" /><pair ddi="false" e1="DDI-PubMed.20032533.s7.e4" e2="DDI-PubMed.20032533.s7.e5" /></sentence><sentence text=" The major barrier to using adjusted dose protease inhibitors with rifampicin is the high rates of hepatotoxicity seen in healthy volunteers"><entity charOffset="67-77" id="DDI-PubMed.20032533.s8.e0" text="rifampicin" /></sentence><sentence text=" The alternative strategy followed in resource-rich settings is to replace rifampicin with rifabutin, but even if the price of rifabutin were to be dramatically reduced it would be difficult to implement in high-burden countries where standardized antitubercular regimens with fixed-dose combinations are used"><entity charOffset="75-85" id="DDI-PubMed.20032533.s9.e0" text="rifampicin" /><entity charOffset="91-100" id="DDI-PubMed.20032533.s9.e1" text="rifabutin" /><entity charOffset="127-136" id="DDI-PubMed.20032533.s9.e2" text="rifabutin" /><pair ddi="false" e1="DDI-PubMed.20032533.s9.e0" e2="DDI-PubMed.20032533.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20032533.s9.e0" e2="DDI-PubMed.20032533.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s9.e0" e2="DDI-PubMed.20032533.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20032533.s9.e1" e2="DDI-PubMed.20032533.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20032533.s9.e1" e2="DDI-PubMed.20032533.s9.e2" /></sentence><sentence text="" /></document>